Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous blinatumomab in relapsed/refractory or MRD-positive B-cell precursor acute lymphoblastic leukemia
jRCT2031230003Phase 2Active, not recruiting
- Sponsor
- Amgen
- Start
- Jan 2021
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) and B cell acute lymphoblastic leukemia (B-ALL) (5 arms), sponsored by Amgen. Started Jan 2021; status: active, not recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on jRCT2031230003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230003.